BioSpace News Archive

Feb. 12, 2020 12:00 UTC – Completed Last Patient Last Visit for STRIDE 3 Dry Eye Disease Trial; Topline Results on Track for First Quarter of 2020 – – Achieved Full Year 2019 INVELTYS® Revenues of $6.1 Million – – Conference Call and Webcast Today at 8:00 a.m. ET – WATERTOWN, Mass.--( BUSINESS WIRE )-- Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative ther

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will present new data on INBRIJA® (levodopa inhalation powder) and OFF Periods at the upcoming 3rd Pan American Parkinson’s Disease and Movement Disorders Congress (MDS-PAS) taking place February 14-16, 2020 in Miami, FL.

Feb. 12, 2020 12:00 UTC Study to Evaluate the Pressure-Enabled Drug Delivery™ Approach Combined with Standard of Care Chemotherapy to Enable Deep Tumor Penetration and Minimize Dose-Limiting Toxicity DENVER--( BUSINESS WIRE )-- TriSalus Life Sciences, a company committed to developing comprehensive solid tumor solutions, today announced the initiation of a new clinical trial assessing the safety and feasibility of an innovative new treatment that combines its intravascula

Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) (“Liminal BioSciences” or the “Company” ), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, today announced the Company and its collaborators will present scientific findings at two upcoming Keystone Symposia

Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases, today announced it has initiated its first-in-human Phase I clinical trial for ATI-2173, a novel liver-targeted, orally-administered, small molecule against hepatitis B.

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body’s immune system in the fight against cancer, today announced that the research team lead by Dr. Jose Conejo-Garcia, Chair of the Department of Immunology at Moffitt Cancer Center, Anixa’s development partner, has completed and validated the reformulation of the viral vector necessary for its CAR-T program

ADVANZ PHARMA Corp. Limited (“ADVANZ PHARMA” or “the Company”) (TSX: ADVZ), today commented on the issuance by the UK Competition and Markets Authority (“CMA”) of a Supplemental Statement of Objections (“SSO”) in relation to the supply of hydrocortisone tablets in the UK

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) announced today it will reduce debt by $100 million through the redemption of outstanding senior notes, using cash generated from operations.

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the 9th Annual SVB Leerink Global Healthcare Conference in New York City on Wednesday, February 26, 2020, at 1:00 p.m. Eastern time.

ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced the closing of a $105 million Series C equity financing.